DXCM vs. PODD

Last updated Apr 1, 2026

Compare and contrast key facts about DexCom, Inc. (DXCM) and Insulet Corporation (PODD).

Performance

DXCM vs. PODD - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in DexCom, Inc. (DXCM) and Insulet Corporation (PODD). The values are adjusted to include any dividend payments, if applicable.

DXCM vs. PODD - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
DXCM DexCom, Inc.	-5.38%	-14.66%	-37.33%	9.58%	-15.64%	45.23%	69.02%	82.59%	108.75%	-3.87%
PODD Insulet Corporation	-26.18%	8.88%	20.32%	-26.30%	10.64%	4.08%	49.32%	115.83%	14.96%	83.12%

Fundamentals

Market Cap DXCM : $25.05B PODD : $14.83B
EPS DXCM : $2.07 PODD : $3.50
PE Ratio DXCM : 30.40 PODD : 60.00
PEG Ratio DXCM : 0.72 PODD : 0.06
PS Ratio DXCM : 5.45 PODD : 5.47
PB Ratio DXCM : 9.12 PODD : 9.79
Total Revenue (TTM) DXCM : $4.66B PODD : $2.71B
Gross Profit (TTM) DXCM : $2.80B PODD : $1.94B
EBITDA (TTM) DXCM : $1.34B PODD : $456.00M

Returns By Period

In the year-to-date period, DXCM achieves a -5.38% return, which is significantly higher than PODD's -26.18% return. Over the past 10 years, DXCM has underperformed PODD with an annualized return of 14.02%, while PODD has yielded a comparatively higher 20.13% annualized return.

DXCM

• 1D: 1.45%
• 1M: -14.48%
• YTD: -5.38%
• 6M: -6.67%
• 1Y: -8.04%
• 3Y*: -18.54%
• 5Y*: -7.23%
• 10Y*: 14.02%

PODD

• 1D: 0.88%
• 1M: -14.91%
• YTD: -26.18%
• 6M: -32.03%
• 1Y: -20.09%
• 3Y*: -13.03%
• 5Y*: -4.55%
• 10Y*: 20.13%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

DXCM vs. PODD — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DXCM

DXCM Risk / Return Rank: 34
DXCM Sharpe Ratio Rank: 34
DXCM Sortino Ratio Rank: 31
DXCM Omega Ratio Rank: 32
DXCM Calmar Ratio Rank: 37
DXCM Martin Ratio Rank: 37

PODD

PODD Risk / Return Rank: 21
PODD Sharpe Ratio Rank: 19
PODD Sortino Ratio Rank: 18
PODD Omega Ratio Rank: 19
PODD Calmar Ratio Rank: 28
PODD Martin Ratio Rank: 21

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

DXCM vs. PODD - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for DexCom, Inc. (DXCM) and Insulet Corporation (PODD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	DXCM	PODD	Difference
Sharpe ratio Return per unit of total volatility	-0.18	-0.51	+0.33
Sortino ratio Return per unit of downside risk	0.04	-0.60	+0.63
Omega ratio Gain probability vs. loss probability	1.01	0.93	+0.08
Calmar ratio Return relative to maximum drawdown	-0.19	-0.46	+0.27
Martin ratio Return relative to average drawdown	-0.38	-1.14	+0.77
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

DXCM vs. PODD - Sharpe Ratio Comparison

The current DXCM Sharpe Ratio is -0.18, which is higher than the PODD Sharpe Ratio of -0.51. The chart below compares the historical Sharpe Ratios of DXCM and PODD, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	DXCM	PODD	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.18	-0.51	+0.33
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.16	-0.11	-0.05
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.29	0.48	-0.19
Sharpe Ratio (All Time) Calculated using the full available price history	0.29	0.29	0.00

Correlation

The correlation between DXCM and PODD is 0.47, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

DXCM vs. PODD - Dividend Comparison

Neither DXCM nor PODD has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

DXCM vs. PODD - Drawdown Comparison

The maximum DXCM drawdown since its inception was -94.61%, roughly equal to the maximum PODD drawdown of -90.28%. Use the drawdown chart below to compare losses from any high point for DXCM and PODD.

Drawdown Indicators

	DXCM	PODD	Difference
Max Drawdown Largest peak-to-trough decline	-94.61%	-90.28%	-4.33%
Max Drawdown (1Y) Largest decline over 1 year	-38.75%	-41.04%	+2.29%
Max Drawdown (5Y) Largest decline over 5 years	-66.32%	-61.31%	-5.01%
Max Drawdown (10Y) Largest decline over 10 years	-66.32%	-61.31%	-5.01%
Current Drawdown Current decline from peak	-61.43%	-40.52%	-20.91%
Average Drawdown Average peak-to-trough decline	-35.79%	-24.64%	-11.15%
Ulcer Index Depth and duration of drawdowns from previous peaks	19.27%	16.53%	+2.74%

Volatility

DXCM vs. PODD - Volatility Comparison

The current volatility for DexCom, Inc. (DXCM) is 9.22%, while Insulet Corporation (PODD) has a volatility of 10.42%. This indicates that DXCM experiences smaller price fluctuations and is considered to be less risky than PODD based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	DXCM	PODD	Difference
Volatility (1M) Calculated over the trailing 1-month period	9.22%	10.42%	-1.20%
Volatility (6M) Calculated over the trailing 6-month period	27.63%	24.33%	+3.30%
Volatility (1Y) Calculated over the trailing 1-year period	43.67%	39.49%	+4.18%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	46.76%	42.04%	+4.72%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	48.31%	42.20%	+6.11%

Financials

DXCM vs. PODD - Profitability Comparison

The chart below illustrates the profitability comparison between DexCom, Inc. and Insulet Corporation over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

DXCM - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, DexCom, Inc. reported a gross profit of 792.70M and revenue of 1.26B. Therefore, the gross margin over that period was 62.9%.

PODD - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Insulet Corporation reported a gross profit of 568.60M and revenue of 783.80M. Therefore, the gross margin over that period was 72.5%.

DXCM - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, DexCom, Inc. reported an operating income of 323.00M and revenue of 1.26B, resulting in an operating margin of 25.6%.

PODD - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Insulet Corporation reported an operating income of 146.30M and revenue of 783.80M, resulting in an operating margin of 18.7%.

DXCM - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, DexCom, Inc. reported a net income of 267.30M and revenue of 1.26B, resulting in a net margin of 21.2%.

PODD - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Insulet Corporation reported a net income of 101.60M and revenue of 783.80M, resulting in a net margin of 13.0%.